$AGEN Possible C&H breakout

Agenus (NASDAQ:AGEN) inks an agreement with Hangzhou-based Betta Pharmaceuticals for the development and commercialization of PD-1 inhibitor balstilimab and CTLA-4 inhibitor zalifrelimab in Greater China, including the mainland, Hong Kong, Macau and Taiwan.

Under the terms of the deal, AGEN will receive $15M in upfront cash plus a $20M equity investment, up to $100M in milestones and royalties on net sales. Betta will have exclusive rights to both drugs either as monotherapies or in combination, exclusive of intravesical (drug administered directly into the bladder) delivery.
Your Intro To Penny Stock Trading Success...

1) Sign Up for our 100% Free Email Newsletter:

2) Follow our Telegram Channel @

3) Join our LIVE CHAT on Discord @


Home Stock Screener Forex Screener Crypto Screener Economic Calendar How It Works Chart Features Pricing Refer a friend House Rules Help Center Website & Broker Solutions Widgets Charting Solutions Lightweight Charting Library Blog & News Twitter
Profile Profile Settings Account and Billing Refer a friend My Support Tickets Help Center Ideas Published Followers Following Private Messages Chat Sign Out